EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Successful concomitant therapy with tofacitinib for anti- melanoma differentiation associated gene 5 antibody-positive rapidly progressive interstitial lung disease with poor prognostic factors

Tomoaki Machiyama, Tsuyoshi Shirai, Yoko Fujita, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

Medicine: Case Reports and Study Protocols · 2021

DOI: 10.1097/md9.0000000000000026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine: Case Reports and Study Protocols, 2021. Verfasst von Tomoaki Machiyama und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Rapidly progressive interstitial lung disease (RP-ILD) is a severe complication of anti- melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis and has an extremely poor prognosis. Patient concerns: We describe the case of a 62-year-old Japanese male with progressive hypoxemia. Laboratory examinations revealed elevated levels of serum ferritin, KL-6, myogenic enzymes, liver enzyme, inflammatory markers and Anti-MDA5-antibody positivity. Chest computed tomography revealed consolidation along the bronchovascular bundle with air bronchograms, predominantly in the inferior lobe of both lungs. Diagnosis: The patient was diagnosed as anti-MDA5 antibody-positive RP-ILD.

Interventions

Respiratory failure continued to worsen even after conventional therapy with glucocorticoids and intravenous cyclophosphamide. Due to the severity of his symptoms, tofacitinib was used in combination with tacrolimus, rituximab, and plasma exchange. Outcomes: The severity of his respiratory symptoms dramatically decreased and he was discharged without the need for supplemental oxygen. Lessons: This case suggests that multi-target immunosuppressive therapy including tofacitinib can be useful for anti-MDA5 antibody-positive RP-ILD in patients with poor prognostic factors.

Zitieren

APA

Machiyama, T., Shirai, T., Fujita, Y., Sato, H., Fujii, H., Ishii, T., & Harigae, H. (2021). Successful concomitant therapy with tofacitinib for anti- melanoma differentiation associated gene 5 antibody-positive rapidly progressive interstitial lung disease with poor prognostic factors. Medicine: Case Reports and Study Protocols. https://doi.org/10.1097/md9.0000000000000026

Vancouver

Machiyama T, Shirai T, Fujita Y, Sato H, Fujii H, Ishii T, et al. Successful concomitant therapy with tofacitinib for anti- melanoma differentiation associated gene 5 antibody-positive rapidly progressive interstitial lung disease with poor prognostic factors. Medicine: Case Reports and Study Protocols. 2021. doi:10.1097/md9.0000000000000026

BibTeX
@article{Machiyama2021,
  author = {Machiyama, Tomoaki and Shirai, Tsuyoshi and Fujita, Yoko and Sato, Hiroko and Fujii, Hiroshi and Ishii, Tomonori and Harigae, Hideo},
  title = {Successful concomitant therapy with tofacitinib for anti- melanoma differentiation associated gene 5 antibody-positive rapidly progressive interstitial lung disease with poor prognostic factors},
  journal = {Medicine: Case Reports and Study Protocols},
  year = {2021},
  doi = {10.1097/md9.0000000000000026}
}
Kostenlos starten →